Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Macitentan - Johnson & Johnson Innovative Medicine

Next Previous
X
Search
Drug Profile

Macitentan - Johnson & Johnson Innovative Medicine

Alternative Names: ACT-064992; Actelion-1; JNJ-67896062; JNJ-67896062-AAA; JNJ-67896062-AAA-G004; OPSUMIT; Opsumit; Zependo

Latest Information Update: 01 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Actelion Pharmaceuticals; Johnson & Johnson Innovative Medicine; Nippon Shinyaku
  • Class Antifibrotics; Antihypertensives; Antineoplastics; Bromobenzenes; Cardiovascular therapies; Heart failure therapies; Pyrimidines; Skin disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase III Eisenmenger complex; Pulmonary hypertension
  • Phase II Heart failure
  • Discontinued Congenital heart defects; Glioblastoma; Idiopathic pulmonary fibrosis; Portal hypertension; Skin ulcer

Most Recent Events

  • 25 Jul 2024 Discontinued - Clinical-Phase-Unknown for Portal hypertension in France, Czech Republic, Brazil, Germany, Spain, United Kingdom, USA (PO) prior to July 2024 (Johnson & Johnson pipeline, July 2024)
  • 25 Jul 2024 Discontinued - Phase-III for Congenital heart defects (In adolescents, In children, In the elderly, In adults) in Taiwan, Poland, Czech Republic, Canada, United Kingdom, New Zealand, France, China, Australia, Denmark, Denmark, Germany, USA (PO) prior to July 2024 (Johnson & Johnson pipeline, July 2024)
  • 25 Jul 2024 CHMP recommends approval of macitentan for Pulmonary arterial hypertension (In adolescents, In Children) in the European Union

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top